Rizzoli is an internist and endocrinologist whose career has focused on metabolic bone diseases, osteoporosis, and disorders of mineral metabolism. He is Emeritus Professor of Medicine at the University Hospitals of Geneva, where he previously headed the Service of Bone Diseases and chaired the Department of Rehabilitation and Geriatrics. His clinical and research background spans the complex biological systems that regulate skeletal strength, including calcium and phosphate balance, bone remodeling, endocrine signaling, and the effects of aging on musculoskeletal function. These areas are central to modern osteoporosis medicine because skeletal fragility is not determined by bone mineral density alone. Bone architecture, cortical porosity, turnover rate, previous fractures, falls, muscle function, and exposure to medications can all influence a patient’s risk.

The new editor-in-chief brings extensive experience in scientific publishing. He previously served as Editor-in-Chief of Calcified Tissue International, was an editor of BONE, and has worked as an Associate Editor of Osteoporosis International. He also chaired the IOF Committee of Scientific Advisors and currently chairs the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, known as ESCEO. Such roles place Rizzoli at the intersection of research evaluation, clinical practice, and health policy. Editorial leadership in this field requires more than selecting technically sound manuscripts; it also involves identifying studies that can change clinical decisions, clarify uncertainty, and improve prevention strategies for populations at risk of fracture.

In his new role, Rizzoli will work with the US Editor-in-Chief, who is appointed by the Bone Health and Osteoporosis Foundation, as well as the journals’ editorial boards, authors, reviewers, and IOF. The joint structure reflects the international nature of osteoporosis research. Although the disease is often associated with older women, osteoporosis affects people of all sexes and ethnic backgrounds, and its causes and consequences vary across regions. Hip, vertebral, and wrist fractures can lead to chronic pain, reduced mobility, loss of independence, and increased mortality. The burden is expected to grow as populations age, making international collaboration essential for comparing fracture rates, evaluating screening strategies, and adapting treatments to different healthcare systems.

“Osteoporosis International” publishes research across the spectrum of bone disease, including original investigations, reviews, educational articles, and case reports. Its scientific scope ranges from clinical trials and observational studies to laboratory research that has direct relevance to human disease. This breadth is important because osteoporosis is produced by a dynamic imbalance between bone resorption and bone formation. Specialized cells called osteoclasts break down old bone, while osteoblasts create new tissue. In healthy adult bone, these processes are tightly coupled. With aging, hormonal changes, chronic inflammation, nutritional deficiencies, certain cancers, and some medications, resorption may outpace formation, gradually weakening the skeleton and increasing the likelihood that an ordinary fall will cause a fracture.

The journals also provide a platform for research into how osteoporosis is diagnosed and treated. Dual-energy X-ray absorptiometry, or DXA, remains the standard method for measuring bone mineral density at the hip and spine, but clinicians increasingly combine DXA results with clinical risk factors. Tools such as FRAX estimate the probability of a major osteoporotic fracture or hip fracture over a defined period by incorporating age, sex, previous fracture, family history, glucocorticoid use, smoking, alcohol intake, rheumatoid arthritis, and other variables. Researchers are also investigating vertebral fracture assessment, high-resolution imaging, bone turnover markers, artificial intelligence, and genetic risk scores. These approaches may help identify individuals whose bone structure is fragile even when their bone density does not fall below conventional diagnostic thresholds.

Treatment research is equally active. Established antiresorptive medicines, including bisphosphonates and denosumab, reduce bone breakdown and can lower fracture risk, while anabolic and bone-forming therapies stimulate new bone formation in selected patients at very high risk. However, the most appropriate treatment depends on fracture history, kidney function, age, other illnesses, medication access, and the potential risks associated with stopping or changing therapy. Long-term management can be challenging because osteoporosis is often silent until a fracture occurs. Patients may discontinue treatment when they feel well, while clinicians must balance the benefits of fracture prevention against uncommon but serious adverse events. Rigorous evidence and clear clinical guidance are therefore essential, particularly as newer therapies and treatment sequences enter routine practice.

Rizzoli said he was honored to take on the position and expressed his intention to build on the journal’s reputation as a leading publication in osteoporosis and metabolic bone diseases. He emphasized the importance of rigorous, impactful, peer-reviewed research that can advance scientific knowledge, inform clinical practice, and improve musculoskeletal health worldwide. That mission is increasingly urgent because osteoporosis intersects with several of the largest health challenges of the twenty-first century, including population aging, multimorbidity, disability, healthcare inequality, and the rising cost of long-term care. Preventing a fracture can preserve mobility and independence, but doing so often requires earlier identification of risk and coordinated intervention involving primary care, endocrinology, geriatrics, rehabilitation, radiology, nursing, and public health.

The appointment also closes an 18-year editorial chapter under Kanis, whose leadership helped strengthen the international profile of Osteoporosis International. During his tenure, the journal attracted research from around the world and reinforced its position as one of the leading publications in osteoporosis and metabolic bone disease. IOF President Professor Nicholas Harvey credited Kanis with helping shape the journal’s scientific standing and establishing a strong foundation for its future. The transition reflects the continuity of a publication while acknowledging changes in the science itself: osteoporosis research now extends from molecular mechanisms and drug development to fracture liaison services, fall prevention, digital health, health economics, and strategies designed to close treatment gaps after a first fracture.

The IOF, described as the world’s largest nongovernmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases, represents scientific, medical, research, and patient organizations in 152 countries. Its leadership argues that fracture prevention and healthy mobility should become global healthcare priorities. With Rizzoli scheduled to begin his editorial term in 2026, the European Office will enter its next phase amid rapid advances in bone biology, precision medicine, and population health. The central test for the journals will be to ensure that emerging discoveries are evaluated with methodological rigor and translated into evidence that can help clinicians prevent fractures, preserve mobility, and reduce the worldwide consequences of skeletal fragility.

Subject of Research: Appointment of Professor René Rizzoli as Editor-in-Chief for the European Office of Osteoporosis International and Archives of Osteoporosis.

Article Title: René Rizzoli Appointed to Lead European Editions of Major Osteoporosis Journals

Web References: International Osteoporosis Foundation, https://www.osteoporosis.foundation/

Keywords: Osteoporosis, bone health, metabolic bone disease, osteoporosis research, René Rizzoli, Osteoporosis International, Archives of Osteoporosis, scientific publishing, fracture prevention, bone mineral density, musculoskeletal health, International Osteoporosis Foundation

Bone health is maintained through a delicate balance between osteoblastic bone formation and osteoclastic bone resorption. Aging, hormonal changes, and chronic diseases often tip this balance, leading to pathological bone loss and compromised regenerative capacity. Despite numerous treatments available, many either focus exclusively on inhibiting bone resorption or promoting formation, rarely achieving the ideal synergy necessary for fully restorative therapies. The research team, led by Zheng HL and colleagues, has identified PREP—a serine protease long studied in neurodegenerative and psychiatric disorders—as a pivotal molecular switch capable of modulating this intricate balance in skeletal biology.

Delving deep into cellular and molecular pathways, the study demonstrates that PREP silencing activates anabolic signaling cascades in osteoblasts, significantly enhancing their proliferation, differentiation, and matrix mineralization. Concurrently, the suppression of PREP inhibits osteoclastogenesis and the activity of mature osteoclasts, thereby curtailing bone resorption processes. This bifunctional mechanism underscores the enzyme’s central role in orchestrating bone turnover and offers a unified target for therapeutic intervention that was previously unrecognized.

Utilizing sophisticated gene silencing techniques, including siRNA-mediated knockdown and CRISPR-Cas9 strategies in preclinical models, the research highlights how diminished PREP activity strengthens key bone-forming pathways, notably by upregulating osteogenic markers such as Runx2, Osterix, and alkaline phosphatase. This not only expedites new bone synthesis but also improves the structural quality of the regenerated matrix, which is critical for restoring functional integrity. Additionally, the anti-catabolic dimension was explored through assessments of RANKL-induced osteoclastogenesis, revealing that reduced PREP levels interfere with the differentiation and resorptive capacity of osteoclasts.

These findings were further corroborated by in vivo experiments employing rodent models of osteoporosis induced by ovariectomy, mimicking postmenopausal bone loss in humans. Animals treated with PREP-targeting molecules exhibited remarkable preservation of bone mineral density and microarchitecture compared to controls, accompanied by enhanced markers of bone formation in histological analysis. Importantly, these effects translated to tangible improvements in biomechanical strength, suggesting that PREP silencing not only halts deterioration but actively revitalizes skeletal robustness.

Beyond structural benefits, the study explores the implications of modulating PREP activity on the bone marrow microenvironment, revealing that PREP suppression fosters a more conducive niche for osteoprogenitor recruitment and survival. This microenvironmental optimization appears to synergize with the direct anabolic effects on osteoblasts, accelerating endogenous regenerative processes and potentially shortening recovery timelines following fractures or bone damage.

The mechanistic insights from this research also open intriguing questions about the broader metabolic roles of PREP and its peptide substrates in skeletal tissue. PREP’s involvement in processing proline-containing peptides implicates it in regulatory networks that influence cellular signaling, inflammation, and extracellular matrix remodeling—all critical components in the dynamic remodeling activities of bone. Thus, targeting PREP may exert pleiotropic effects beyond traditional bone cell-centric models, offering a new paradigm in bone biology.

Furthermore, the therapeutic potential of PREP inhibition could extend to inflammatory and degenerative bone diseases, including rheumatoid arthritis and periodontitis, where excessive bone resorption drives morbidity. By attenuating osteoclast activity while amplifying osteoblast function, PREP silencing represents a unique intervention point to recalibrate bone homeostasis under pathological conditions.

While these discoveries herald a promising chapter in bone health management, the translation from preclinical findings to clinical practice mandates rigorous evaluation to elucidate long-term safety, dosing parameters, and potential systemic effects of PREP inhibitors. The enzyme’s established roles in neurological systems caution for off-target impacts, necessitating precision delivery modalities, such as bone-targeted nanoparticles or local administration, to maximize therapeutic windows and minimize adverse events.

In an era where aging populations globally face unprecedented risks of debilitating fractures and skeletal degeneration, the demonstration that manipulation of a single enzyme can both preserve and regenerate bone holds transformative significance. This dual-action approach challenges existing treatment archetypes and suggests a future where bone diseases may be tackled with multifaceted molecular precision, restoring not just quantity but quality and function.

The compelling body of evidence presented by Zheng and colleagues not only advances scientific understanding but also ignites renewed optimism for patients suffering from bone loss disorders. It sets a new benchmark for research into serine proteases as key modulators beyond their classical biochemical roles, extending into tissue regeneration and repair.

As ongoing studies continue to unravel the intricacies of PREP’s physiological influence and explore combinatory treatment frameworks with current bone anabolic agents, the prospects for clinical breakthroughs remain bright. Emerging pharmaceutical development programs inspired by these findings could soon usher in a new class of bone therapeutics that decisively improve outcomes for millions worldwide.

Ultimately, this pioneering work affirms that unraveling the hidden regulatory nodes within bone remodeling circuits enables innovative solutions that were once thought elusive. With continued interdisciplinary collaboration and technological advances, harnessing enzymes like prolyl endopeptidase may dismantle long-standing barriers in skeletal medicine and reshape the paradigm of bone disease treatment for generations to come.

Subject of Research: Prolyl endopeptidase silencing and its effects on bone loss prevention and regeneration.

Article Title: Silencing of prolyl endopeptidase protects against bone loss and enhances regeneration via bone anabolic and anti-catabolic effects.

Article References: Zheng, HL., Cai, H., Chen, PB. et al. Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02905-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02905-y